Treatment for uterine fibroids: Searching for effective drug therapies

Drug Discovery Today: Therapeutic Strategies

Volumn 9, Issue 1, 2012, Pages

  Taylor, Darlene K ^a,b   Leppert, Phyllis C ^b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOLBIFENE; ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; ASOPRISNIL; BUSERELIN; CLOSTRIDIOPEPTIDASE A; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HALOFUGINONE; HISTRELIN; LETROZOLE; LEUPRORELIN; LEVONORGESTREL; MIFEPRISTONE; NAFARELIN; NANOCARRIER; ORAL CONTRACEPTIVE AGENT; PIRFENIDONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRIPTORELIN; ULIPRISTAL;

BINDING AFFINITY; CHINESE MEDICINE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; LOW DRUG DOSE; PHARMACODYNAMICS; REVIEW; UTERUS MYOMA;

EID: 84871433297     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2012.06.001     Document Type: Review

References (48)

1. Peddada, S.D. et al. (2008) Growth of uterine leiomyomata among premenopausal black and white women. Proc. Natl. Acad. Sci. U.S.A. 105, 19887-19892
2. Leppert, P.C. et al. (2006) A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am. J. Obstet. Gynecol. 195, 415-420 (Pubitemid 44142369)
3. Catherino, W. et al. (2004) Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 40, 204-217 (Pubitemid 38703097)
4. Carrino, D.A. et al. (2012) Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition. Biochem. J. 443, 361-368. This report presents evidence that uterine fibroids are characterized by disarrayed collagen fibrils strikingly similar to those of keloid scars. The authors find that keloids are a form of excessive dermal fibrosis demonstrating abnormal wound-healing response in certain individuals; they form after skin trauma such as surgery; they tend to develop during and after puberty and in women symptoms of keloids disappear after menopause; they produce high levels of collagen, and fibronectin; they are characterized as resisting apoptosis and thus continue to produce collagen.
5. Cook, H. et al. (2010) The impact of uterine leiomyomas on reproductive outcomes. Minerva Ginecol. 62, 225-236
6. Bouwsma, E.V. et al. (2011) Comparing focused ultrasound and uterine artery embolization for uterine fibroids-rationale and design of the fibroid interventions: reducing symptoms today and tomorrow (firstt) trial. Fertil. Steril. 96, 704-710
7. Parsanezhad, M. et al. (2012) Medical management of uterine fibroids. Curr. Obstet. Gynecol. Rep. 1-8
8. Cardozo, E.R. et al. (2011) The estimated annual cost of uterine leiomyomata in the united states. Am. J. Obstet. Gynecol. . The article reports than annual societal costs for uterine fibroid therapy approach $34.4 billion not accounting for those women with symptomatic fibroids and no access to medical care. The authors use pooled odds ratios when possible and reflect a large number of studies, to arrive at numbers for direct, indirect, and associated pregnancy and obstetrical related costs in the assessment of cost of uterine fibroids.
9. Wikland, M. et al. (2011) A randomized controlled study comparing pain experience between a newly designed needle with a thin tip and a standard needle for oocyte aspiration. Hum. Reprod. 26, 1377-1383
10. Wright, J.C. et al. (2012) In situ forming systems (depots). In Long acting injections and implants (Wright, J.C. and Burgess, D.J., eds), pp. 153-166, Springer
11. Taylor, D.K. et al. (2011) Temperature-responsive biocompatible copolymers incorporating hyperbranched polyglycerols for adjustable functionality. J. Funct. Biomater. 2, 173-194. The authors describe the design, synthesis, and characterization of a four component copolymer that responds to elevation in temperature by undergoing a phase transition from liquid to solid. This is the first thermoresponsive injectable that has the potential to deliver multiple drugs by mechanistically different approaches: covalent attachment of drug and physical entrapment of drug.
12. del Mastro, L. et al. (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. J. Am. Med. Assoc. 306, 269-276
13. Sabry, M. and Al-Hendy, A. (2012) Innovative oral treatments of uterine leiomyoma. Obstet. Gynecol. Int. http://dx.doi.org/10.1155/2012/943635. This review of drug therapies covers conventional drugs in a very succinct manner. In addition, the authors include a section on herbal therapies.
14. Khan, K.N. et al. (2010) Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after gnrh agonist therapy. Hum. Reprod. 25, 642-653
15. McCarthy-Keith, D.M. et al. (2011) Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells. Fertil. Steril. 95, 2383-2387. The authors characterize hyperosmolarity-responsive genes in leiomyoma cells and determine whether gonadotropin-releasing hormone (GnRH) agonist treatment altered their expression. This report is timely because it offers insight into yet another mechanism of fibroid shrinkage.
16. Gobbi, S. et al. (2010) Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure- activity relationships investigation. J. Med Chem. 53, 5347-5351. This is one of a series of papers that reports on some molecules featuring different oxygenated heterocycles such as flavone, chromone, and xanthone asaromatase inhibitors. The authors are focusing on development of novel AI constructs with the aim of increasing potency and selectivity versus other CYP enzymes.
17. Saudagar, R.B. et al. (2011) Serm's in treatment of breast cancer. Asian J. Pharm. Res. 1, 81-86
18. Dai, X. and Wu, J. (2011) Selective estrogen receptor modulator: raloxifene. J. Reprod. Contracept. 22, 51-60. This paper compiles a lot of the previously reported findings on raloxifene. It also has general discussion about SERMs as a drug class.
19. Bouchard, P. et al. (2011) Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil. Steril. 96, 1175-1189. This paper serves as the first recent review of SPRMs and compiles a lot of the previously reported findings for this drug class. Thus, it is a timely contribution to the field.
20. Catherino, W.H. et al. (2011) Proceedings from the national institute of child health and human development conference on the uterine fibroid research update workshop. Fertil. Steril. 95, 9-12
21. Chai, S.Y. et al. (2012) Term myometrium is characterized by increased activating epigenetic modifications at the progesterone receptor-a promoter. Mol. Hum. Reprod. http://dx.doi.org/10.1093/molehr/gas012
22. Crochet, J.R. et al. (2011) Mitochondrial progesterone receptor (pr-m) distribution in uterine leiomyoma and myometrium and impact on mitochondrial membrane potential (mmp) in immortilized human myometrial cells (htert-hm). Fertil. Steril. 96, S96. In providing evidence of increase PR-M expression and number of mitochondria in the fibroids edge, these authors present evidence that a non-genomic progestininduced increase in cellular respiration may be a major factor in the growth of fibroids.
23. Richardson, T.I. et al. (2011) Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids. ACS Med. Chem. Lett. 2, 148-153
24. Spitz, I.M. (2010) Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century Contraception 82, 442-452. This paper serves as the current review of milepristone compiling results over 25 years.
25. Esteve, J.L.C. et al. (2012) Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 161, 202-208
26. Heikinheimo, O. and Gemzell-Danielsson, K. (2012) Emerging indications for the levonorgestrel-releasing intrauterine system (lng-ius). Acta Obstet. Gynecol. Scand. 91, 3-9
27. Sayed, G.H. et al. (2011) A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int. J. Gynecol. Obstet. 112, 126-130
28. Kriplani, A. et al. (2012) Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int. J. Gynecol. Obstet. 116, 35-38
29. Stovall, D.W. and Mikdachi, H.E. (2011) Treatment of symptomatic uterine leiomyomas with selective progesterone receptor modulators. Expert Rev. Obstet. Gynecol. 6, 579-582
30. Rodriguez, M.I. et al. (2010) Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications. Am. J. Obstet. Gynecol. 202, 420-428
31. Donnez, J. et al. (2012) Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 366, 409-420
32. Nieman, L.K. et al. (2011) Efficacy and tolerability of cdb-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebocontrolled, phase iib study. Fertil. Steril. 95, 767-769
33. Luo, X. et al. (2010) The selective progesterone receptor modulator cdb4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil. Steril. 93, 2668-2673
34. Roeder, H. et al. (2011) Cdb-4124 does not cause apoptosis in cultured fibroid cells. Reprod. Sci. 18, 850-857. This report is a major finding as it corrects previous thoughts on the role of CDB-4124.
35. Wade, H.E. et al. (2010) Multimodal regulation of e2f1 gene expression by progestins. Mol. Cell. Biol. 30, 1866-1877
36. Leask, A. (2010) Potential therapeutic targets for cardiac fibrosis: Tgfbeta, angiotensin, endothelin, ccn2, and pdgf, partners in fibroblast activation. Circ. Res. 106, 1675-1680
37. Malik, M. et al. (2010) Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin. Reprod. Med. 28, 169-179
38. Norian, J.M. et al. (2012) Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma. Matrix Biol. 31, 57-65
39. Iwahashi, M. and Muragaki, Y. (2011) Increased type i and v collagen expression in uterine leiomyomas during the menstrual cycle. Fertil. Steril. 95, 2137-2139
40. Fritz, D. et al. (2011) Progress towards discovery of antifibrotic drugs targeting synthesis of type i collagen. Curr. Med. Chem. 18, 3410-3416. This paper serves as the first recent review of antifibrotic drugs. The authors compile a lot of the previously reported findings within this drug class.
41. Cho, M.E. and Kopp, J.B. (2010) Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin. Investig. Drugs 19, 275-283
42. Macias-Barragan, J. et al. (2010) The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Rep. 3, 16. This is concise review of the chemical and biological properties of pirfenidone. The authors have captured not only major previous reports on this drug, but in addition, given insight into what we can expect from pharmaceutical development within this drug class.
43. InterMune (2011) A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Brisbane, California. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2012 Jul 23]. Available from: http://clinicaltrials.gov/show/NCT01366209 NLM Identifier: NCT01366209
44. Grudzien, M.M. et al. (2010) The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil. Steril. 93, 1290-1298
45. Tantibhedhyangkul, J.A. and Behera, M. (2010) Non-surgical treatment options for symptomatic uterine leiomyomas. Curr. Womens Health Rev. 6, 146-160
46. Su, Y. et al. (2012) Contraceptives with novel benefits. Expert Opin. Investig. Drugs 21, 83-90
47. Liu, W.J.H. (2011) Introduction to traditional herbal medicines and their study. In Traditional herbal medicine research methods (Liu, W.J.H., ed.), pp. 1-26, John Wiley & Sons, Inc
48. Balch, P.A. and Bell, S. (2012) Prescription for herbal healing, 2nd edn: An easy-to-use a-to-z reference to hundreds of common disorders and their herbal remedies. Penguin Group